News

  • FUJIFILM STARTS A U.S. PHASE I CLINICAL TRIAL OF ANTI-CANCER AGENT “FF-10850” ON ADVANCED SOLID TUMORS

    FUJIFILM Corporation (President: Kenji Sukeno) announced the start of a U.S. Phase I clinical trial of FF-10850, an anti-cancer agent targeting advanced solid tumors. FF-10850 is a liposome-based agent in which topotecan*1, an approved anti-cancer agent, has been encapsulated in the newly developed liposome. The study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FF-10850. As a drug delivery system (DDS), liposomes are artificially constructed vesicles made from the organic phospholipids which make up cellular membranes and biomembranes. Liposomes […]

    Read More

  • Fujifilm Commits to Further Research on Nucleic Acid-liposome drug delivery system

    FUJIFILM Corporation (President: Kenji Sukeno) announced today that Fujifilm is working towards improving the development of nucleic acid therapeutics by using liposomal drug delivery systems. Fujifilm’s liposomal drug delivery systems are created from its expertise in advanced nanodispersion and analytical technologies. The drug delivery formulation is also used in its anti-cancer drug candidate “FF-10832”, a liposomal gemcitabine formulation, which is being evaluated in a US Phase 1 clinical trial. In support of these continuing efforts, Fujifilm has engaged in a research collaboration with the Anderson Lab at the […]

    Read More

  • Research results for FF-10850, a novel liposome drug candidate for improvement of pharmacological efficacy through selective delivery of anti-cancer agent to tumors

    FUJIFILM Corporation (President: Kenji Sukeno) has succeeded in stably encapsulating the anti-cancer agent topotecan*1, approved for the treatment of several solid cancers, in newly invented liposome. When preclinical studies in mice were conducted using a drug where topotecan was encapsulated in liposomes (development number: FF-10850), in addition to confirming high tumor shrinking effects, improved pharmacological efficacy was demonstrated when administered in combination with an immune checkpoint inhibitor*2 , with prolonged survival compared to monotherapy. Going forward, based on the results […]

    Read More

  • RESEARCH RESULTS FOR FF-10832, A NOVEL LIPOSOME DRUG CANDIDATE FOR IMPROVEMENT OF PHARMACOLOGICAL EFFICACY THROUGH SELECTIVE DELIVERY OF ANTI-CANCER AGENT TO TUMORS

    FUJIFILM Corporation (President: Kenji Sukeno) has announced the drug release mechanism of continuous action in tumors for the anti-cancer agent FF-10832, currently undergoing Phase I clinical trials in the United States. In addition, it has also been observed that improved pharmacological efficacy is demonstrated when administered in combination with an immune checkpoint inhibitor*1, with prolonged survival compared to monotherapy. These research results have been clarified through preclinical study in mice. FF-10832 is a liposome-based agent in which gemcitabine*2, an […]

    Read More

  • FUJIFILM ANNOUNCES LAUNCH OF FUJIFILM TOYAMA CHEMICAL

    FUJIFILM Corporation (President: Kenji Sukeno) announces the launch of FUJIFILM Toyama Chemical Co., Ltd (President: Junji Okada) on October 1, 2018. The company will engage in the research, development, manufacture and sale of diagnostic and therapeutic drugs. FUJIFILM Toyama Chemical was formed through the merger of TOYAMA CHEMICAL CO., LTD. (Toyama Chemical), a company engaged in the research, development, manufacture and sale of small molecule pharmaceuticals and FUJIFILM RI Pharma Co., Ltd., a company engaged in the […]

    Read More

  • Fujifilm Accelerates New Drug Development for Diagnostic and Therapeutic Drugs Through the Merger of Group Companies to Form FUJIFILM Toyama Chemical Co., Ltd.

    FUJIFILM Holdings Corporation (President: Kenji Sukeno) today announced it plans to mergeTOYAMA CHEMICAL CO., LTD., a company that conducts the research, development, manufacture, and sales of small molecule pharmaceutical products, and FUJIFILM RI Pharma Co., Ltd., a company that conducts the research, development, manufacture, and sales of radiopharmaceuticals, to form FUJIFILM Toyama Chemical Co., Ltd. as of October 1, 2018 in order to accelerate the development of new diagnostic and therapeutic […]

    Read More

  • Fujifilm Starts a U.S. Phase I Clinical Trial of Anti-Cancer Agent FF-10832 on Advanced Solid Tumors

    FUJIFILM Corporation (President: Kenji Sukeno) announced the start of a U.S. Phase I clinical trial of the anti-cancer agent FF-10832 for advanced solid tumors. FF-10832 is a liposome-based agent in which the existing water-soluble anti-cancer agent gemcitabine*1 is encapsulated in liposomes by harnessing Fujifilm’s advanced nano-dispersion technology, analysis technology, and process technology cultivated through the photographic film business. Liposomes are artificially constructed vesicles made from the same organic phospholipids that make up cell and […]

    Read More

  • Drug Discovery Identification of a Novel Compound that Boosts the Rehabilitation Effects after Stroke

    —Published in Science— A research group led by Professor Takuya Takahashi, Department of Physiology, Yokohama City University Graduate School of Medicine and Toyama Chemical Co., Ltd. of the Fujifilm Group has identified a new drug candidate that boosts the rehabilitation effects after stroke in collaboration with the National Institute of Advanced Industrial Science and Technology and […]

    Read More

  • ANNOUNCEMENT ON THE START OF PATIENT ENROLLMENT FOR PHASE III CLINICAL STUDY IN JAPAN OF THE ANTIVIRAL DRUG FAVIPIRAVIR FOR IXODID TICK-BORNE INFECTIOUS DISEASE, SERIOUS FEVER WITH THROMBOCYTOPENIA SYNDROME (SFTS)

    Toyama Chemical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Junji Okada), a FUJIFILM Company, has announced that it has started to enroll patients for phase III clinical study in Japan of the antiviral drug favipiravir for ixodid tick-borne infectious disease, serious fever with thrombocytopenia syndrome (SFTS). Favipiravir is a drug that has already obtained marketing authorization as an anti-influenza virus drug […]

    Read More